{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:06:26Z","timestamp":1792710386134,"version":"4.5.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,7,15]]},"DOI":"10.2169\/internalmedicine.0308-17","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T22:18:18Z","timestamp":1519769898000},"page":"2071-2075","source":"Crossref","is-referenced-by-count":19,"title":["Adult T-cell Leukemia\/Lymphoma as a Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis"],"prefix":"10.2169","volume":"57","author":[{"given":"Ichiro","family":"Takajo","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan"},{"name":"Youkikai Ikei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Umekita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Ikei","sequence":"additional","affiliation":[{"name":"Youkikai Ikei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42: 564-571, 2015.","DOI":"10.3899\/jrheum.140533"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int 31: 1487-1492, 2011.","DOI":"10.1007\/s00296-010-1524-0"},{"key":"3","unstructured":"3. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34: 322-331, 2007."},{"key":"4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2017.01.006","volume":"85","author":"A Berti","year":"2018","unstructured":"4. Berti A, Felicetti M, Peccatori S, et al. EBV-induced lymphoproliferative disorders in rheumatic patients: a systematic review of the literature. Joint Bone Spine 85: 35-40, 2018.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013.","DOI":"10.1111\/ejh.12116"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66: 1302-1309, 2014.","DOI":"10.1002\/acr.22306"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 101: 1309-1313, 2010.","DOI":"10.1111\/j.1349-7006.2010.01517.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82: 1106-1109, 2007.","DOI":"10.1002\/ajh.21003"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 22: 5131-5140, 2003.","DOI":"10.1038\/sj.onc.1206551"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res 20: 5217-5225, 2014.","DOI":"10.1158\/1078-0432.CCR-14-0572"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 84: 327-335, 2012.","DOI":"10.1002\/jmv.23181"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Harigai M, Nanki T, Koike R, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying anti rheumatic drugs compared to the general population: a nationwide cohort study in Japan. Mod Rheumatol 26: 642-650, 2016.","DOI":"10.3109\/14397595.2016.1141740"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura H, Ueki Y, Saito S, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med 52: 1983-1986, 2013.","DOI":"10.2169\/internalmedicine.52.0468"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bittencourt AL, Oliveira PD, Bittencourt VG, Carvalho EM, Farre L. Adult T-cell leukemia\/lymphoma triggered by adalimumab. J Clin Virol 58: 494-496, 2013.","DOI":"10.1016\/j.jcv.2013.07.011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hashiba Y, Hidaka T, Umekita K, et al. Remission of chronic type ATL in a patient with rheumatoid arthritis after withdrawing methotrexate and anti-TNF\u03b1 biologic combination therapy; a case report. Modern Rheum Case Reports 2: 9-13, 2018.","DOI":"10.1080\/24725625.2017.1372060"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin&apos;s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131: 73-79, 2005.","DOI":"10.1007\/s00432-004-0600-9"},{"key":"18","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/1097-0142(19940601)73:11<2753::AID-CNCR2820731117>3.0.CO;2-X","volume":"73","author":"S Kamihira","year":"1994","unstructured":"18. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73: 2753-2757, 1994.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219, 2010.","DOI":"10.1182\/blood-2009-12-257410"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Okayama A, Stuver S, Matsuoka M, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia\/lymphoma in asymptomatic carriers. Int J Cancer 110: 621-625, 2004.","DOI":"10.1002\/ijc.20144"},{"key":"21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/01.tp.0000235186.30113.c7","volume":"82","author":"N Kawano","year":"2006","unstructured":"21. Kawano N, Shimoda K, Ishikawa F, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 82: 840-843, 2006.","journal-title":"Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1337","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Soyama A, Eguchi S, Takatsuki M, et al. Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transpl. Liver Transpl 14: 647-650, 2008.","DOI":"10.1002\/lt.21414"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/14\/57_0308-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T04:52:05Z","timestamp":1532148725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/14\/57_0308-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,15]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0308-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,15]]}}}